DOI: https://doi.org/10.22141/2224-0551.6.57.2014.75743

Drugs Modulating TLR Activity

A.Ye. Abaturov, A.P. Volosovets, Ye.I. Yulish

Abstract


The review presents characteristics of drugs being developed that modulate Toll-like receptors activity and can be applied in the treatment of infectious, chronic inflammatory, autoimmune, allergic diseases, malignancies.

Keywords


therapy; infectious process; Toll-like receptors.

References


Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model / K. Takashima, N. Matsunaga, M. Yoshimatsu, K. Hazeki, T. Kaisho, M. Uekata, O. Hazeki, S. Akira, Y. Iizawa, M. Ii // Br. J. Pharmacol. — 2009. — Vol. 157, № 7. — P. 1250-1262. — doi: 10.1111/j.1476-5381.2009.00297.x.

Barochia A.V., Cui X., Natanson C., Eichacker P.Q. Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis // Crit. Care Med. — 2010. — Vol. 38, № 1. — P. 306-308. — doi: 10.1097/CCM.0b013e3181b77fe3.

Cancer and inflammation: promise for biologic therapy / S. Demaria, E. Pikarsky, M. Karin, L.M. Coussens, Y.C. Chen, E.M. El-Omar, G. Trinchieri, S.M. Dubinett, J.T., Mao E. Szabo, A. Krieg, G.J. Weiner, B.A. Fox, G. Coukos, E. Wang, R.T. Abraham, M. Carbone, M.T. Lotze // J. Immunother. — 2010. — Vol. 33, № 4. — P. 335-351. — doi: 10.1097/CJI.0b013e3181d32e74.

Crespo-Lessmann A., Juárez-Rubio C., Plaza-Moral V. Papel de los receptores toll-like en las enfermedades respiratorias // Archivos de Bronconeumología. — 2010. — Vol. 46, № 3. — P. 135-142. — doi: 10.1016/j.arbres.2009.07.011.

Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury / H. Seki, S. Tasaka, K. Fukunaga, Y. Shiraishi, K. Moriyama, K. Miyamoto, Y. Nakano, N. Matsunaga, K. Takashima, T. Matsumoto, M. Ii, A. Ishizaka, J. Takeda // Inflamm Res. — 2010. — Vol. 59, № 10. — P. 837-845. — doi: 10.1007/s00011-010-0195-3.

Engel A.L., Holt G.E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system // Expert. Rev. Clin. Pharmacol. — 2011. — Vol. 4, № 2. — P. 275-289. — doi: 10.1586/ecp.11.5.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies / A. Barochia, S. Solomon, X. Cui, C. Natanson, P.Q. Eichacker // Expert Opin. Drug Metab. Toxicol. — 2011. — Vol. 7, № 4. — P. 479-494. — doi: 10.1517/17425255.2011.558190.

Gawchik S.M., Saccar C.L. Pollinex Quattro Tree: allergy vaccine // Expert. Opin. Biol. Ther. — 2009. — Vol. 9, № 3. — P. 377-382. — doi: 10.1517/14712590802699596.

Gosu V., Basith S., Kwon O.P., Choi S. Therapeutic applications of nucleic acids and their analogues in Toll-like receptor signa­ling // Molecules. — 2012. — Vol. 17, № 11. — P. 13503-13529. — doi: 10.3390/molecules171113503.

Hennessy E.J., Parker A.E., O'Neill L.A.J. Targeting Toll-like receptors: emerging therapeutics? // Nat. Rev. Drug Disc. — 2010. — Vol. 9, № 4. — P. 293-307. — doi: 10.1038/nrd3203.

Horner A.A. Update on toll-like receptor ligands and allergy: implications for immunotherapy // Curr. Allergy Asthma Rep. — 2006. — Vol. 6, № 5. — P. 395-401.

Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists // Nature medicine. — 2007. — Vol. 3, № 5. — P. 552-559. — doi:10.1038/nm1589.

Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation // Nat. Rev. Drug Discov. — 2006. — Vol. 5. — P. 471-484.

Krishnan J., Lee G., Choi S. Drugs Targeting Toll-like Receptors // Arch. Pharm. Res. — 2009. — Vol 32, № 11. — P. 1485-1502. — doi: 10.1007/s12272-009-2100-6.

Loiarro M., Ruggiero V., Sette C. Targeting TLR/IL-1R signalling in human diseases // Mediators Inflamm. — 2010. — Article ID 674363. — 12 p. — doi: 10.1155/2010/674363.

Makkouk A., Abdelnoor A.M. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents // Immunopharmacol. Immunotoxicol. — 2009. — Vol. 31, № 3. — P. 331-338. — doi: 10.1080/08923970902802926.

Patel P., Salapatek A.M. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine // Expert. Rev. Vaccines. — 2006. — Vol. 5, № 5. — P. 617-629. — doi:10.1586/14760584.5.5.617.

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis / M. Tidswell, W. Tillis, S.P. Larosa, M. Lynn, A.E. Wittek, R. Kao, J. Wheeler, J. Gogate, S.M. Opal // Crit. Care Med. — 2010. — Vol. 38, № 1. — P. 72-83. — doi: 10.1097/CCM.0b013e3181b07b78.

Toll-like Receptor 2 Signaling in CD4(+) T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune Disease / J.M. Reynolds, B.P. Pappu, J. Peng, G.J. Martinez, Y. Zhang, Y. Chung, L. Ma, X.O. Yang, R.I. Nurieva, Q. Tian, C. Dong // Immunity. — 2010. — Vol. 32, № 5. — P. 692-702. — doi: 10.1016/j.immuni.2010.04.010.

Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy / C.F. Nicodemus, L. Wang, J. Lucas, B. Varghese, J.S. Berek // Am. J. Obstet. Gynecol. — 2010. — Vol. 202, № 6. — P. 608.e1-608.e8. — doi: 10.1016/j.ajog.2009.12.001.

Tomillero A., Moral M.A. Gateways to clinical trials // Methods Find. Exp. Clin. Pharmacol. — 2009. — Vol. 31, № 2. — P. 107-146.

Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms / F.J. Barrat, T. Meeker, J.H. Chan, C. Guiducci, R.L. Coffman // Eur. J. Immunol. — 2007. — Vol. 37, № 12. — P. 3582-3586. — doi: 10.1002/eji.200737815.

Tse K., Horner A.A. Update on toll-like receptor-directed therapies for human disease // Ann. Rheum. Dis. — 2007. — Vol. 66, Suppl 3. — P. iii77-80. — doi:10.1136/ard.2007.078998.

Yokota S., Okabayashi T., Fujii N. The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection // Mediators Inflamm. — 2010. — Vol. 2010. — № 184328. — doi: 10.1155/2010/184328.




Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта